Biotech Values

[DewDiligence]

CONR webcast leaves some holes:

CONR is an upstart company attempting to battle the heavyweights in the very large market for drug-eluting stents (#msg-4109165, #msg-3181119).

A recent article in Forbes highlighted the CEO’s checkered past (#msg-5491921), casting a shadow on the company’s ongoing litigation with ANPI over the right to use Paclitaxel (generic Taxol) in the company’s stents.

Today’s CONR webcast at the SG Cowen conference contained no new info, but the performance was consistent with the mindset of an aggressive little company attempting to curry favor on Wall Street at all costs.

On several occasions the CEO made grandiose claims about the superiority of the company’s “Swiss cheese” stent design and then, in a rapid monotone that was the aural equivalent of the fine print at the bottom of an advertisement, he added that such claims were yet to be proven.

The question I most wanted to have answered –what will the company do if ANPI prevails in he Paclitaxel lawsuit?— was never broached.